DB:51B

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Bioventix PLC manufactures and supplies sheep monoclonal antibodies (SMAs) for use in blood-testing machines in hospitals and other labs worldwide.


Snowflake Analysis

Flawless balance sheet with solid track record and pays a dividend.

Share Price & News

How has Bioventix's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 51B has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-3.7%

51B

-2.4%

DE Biotechs

-3.6%

DE Market


1 Year Return

5.0%

51B

-3.2%

DE Biotechs

3.7%

DE Market

Return vs Industry: 51B exceeded the German Biotechs industry which returned -3.2% over the past year.

Return vs Market: 51B exceeded the German Market which returned 3.8% over the past year.


Shareholder returns

51BIndustryMarket
7 Day-3.7%-2.4%-3.6%
30 Day-8.3%-3.7%-2.0%
90 Day-7.8%13.2%13.3%
1 Year9.0%5.0%-3.1%-3.2%6.0%3.7%
3 Yearn/a16.0%14.5%1.1%-6.9%
5 Yearn/a10.8%9.0%7.8%-6.8%

Price Volatility Vs. Market

How volatile is Bioventix's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Bioventix undervalued compared to its fair value and its price relative to the market?

31.24x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 51B (€44) is trading above our estimate of fair value (€18.57)

Significantly Below Fair Value: 51B is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 51B is good value based on its PE Ratio (31.2x) compared to the XE Biotechs industry average (40.9x).

PE vs Market: 51B is poor value based on its PE Ratio (31.2x) compared to the German market (20.9x).


Price to Earnings Growth Ratio

PEG Ratio: 51B is poor value based on its PEG Ratio (6x)


Price to Book Ratio

PB vs Industry: 51B is overvalued based on its PB Ratio (21.1x) compared to the DE Biotechs industry average (2.3x).


Next Steps

Future Growth

How is Bioventix forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

5.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 51B's forecast earnings growth (5.2% per year) is above the savings rate (0.2%).

Earnings vs Market: 51B's earnings (5.2% per year) are forecast to grow slower than the German market (23.4% per year).

High Growth Earnings: 51B's earnings are forecast to grow, but not significantly.

Revenue vs Market: 51B's revenue (7.3% per year) is forecast to grow faster than the German market (5.9% per year).

High Growth Revenue: 51B's revenue (7.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 51B's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Bioventix performed over the past 5 years?

20.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 51B has high quality earnings.

Growing Profit Margin: 51B's current net profit margins (65.3%) are higher than last year (63.3%).


Past Earnings Growth Analysis

Earnings Trend: 51B's earnings have grown significantly by 20% per year over the past 5 years.

Accelerating Growth: 51B's earnings growth over the past year (17.1%) is below its 5-year average (20% per year).

Earnings vs Industry: 51B earnings growth over the past year (17.1%) exceeded the Biotechs industry -1.4%.


Return on Equity

High ROE: 51B's Return on Equity (67.5%) is considered outstanding.


Next Steps

Financial Health

How is Bioventix's financial position?


Financial Position Analysis

Short Term Liabilities: 51B's short term assets (£9.4M) exceed its short term liabilities (£940.2K).

Long Term Liabilities: 51B's short term assets (£9.4M) exceed its long term liabilities (£63.0K).


Debt to Equity History and Analysis

Debt Level: 51B is debt free.

Reducing Debt: 51B has not had any debt for past 5 years.

Debt Coverage: 51B has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: 51B has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Bioventix current dividend yield, its reliability and sustainability?

3.17%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 51B's dividend (3.17%) is higher than the bottom 25% of dividend payers in the German market (1.25%).

High Dividend: 51B's dividend (3.17%) is low compared to the top 25% of dividend payers in the German market (3.83%).


Stability and Growth of Payments

Stable Dividend: 51B's dividends per share have been stable in the past 10 years.

Growing Dividend: 51B's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonable payout ratio (62.1%), 51B's dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.6yrs

Average board tenure


CEO

Peter Harrison (62 yo)

no data

Tenure

UK£322,134

Compensation

Mr. Peter John Harrison, MA, serves as the Chief Executive Officer of Bioventix PLC. Mr. Harrison has worked in the field of antibody technology since 1986 and has extensive experience of the development a ...


CEO Compensation Analysis

Compensation vs Market: Peter's total compensation ($USD423.24K) is below average for companies of similar size in the German market ($USD758.05K).

Compensation vs Earnings: Peter's compensation has been consistent with company performance over the past year.


Board Members

NamePositionTenureCompensationOwnership
Peter Harrison
CEO & Directorno dataUK£322.13k8%
£ 18.4m
Treena Turner
Finance Director & Non-Executive Directorno dataUK£4.28kno data
Bruce Edward Hiscock
CFO & Director0.083yrno datano data
Ian Nicholson
Independent Non-Executive Chairman15.75yrsUK£27.54k0.30%
£ 684.3k
Nicholas McCooke
Independent Non-Executive Director6.58yrsUK£23.41kno data

6.6yrs

Average Tenure

61.5yo

Average Age

Experienced Board: 51B's board of directors are considered experienced (6.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Bioventix PLC's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Bioventix PLC
  • Ticker: 51B
  • Exchange: DB
  • Founded: 2003
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£207.071m
  • Listing Market Cap: UK£229.976m
  • Shares outstanding: 5.21m
  • Website: https://www.bioventix.com

Number of Employees


Location

  • Bioventix PLC
  • 27-28 Eastcastle Street
  • London
  • Greater London
  • W1W 8DH
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BVXPAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPApr 2010
51BDB (Deutsche Boerse AG)YesOrdinary SharesDEEURApr 2010

Biography

Bioventix PLC manufactures and supplies sheep monoclonal antibodies (SMAs) for use in blood-testing machines in hospitals and other labs worldwide. The company offers a portfolio of purified SMAs for thyro ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/02 21:12
End of Day Share Price2020/07/31 00:00
Earnings2019/12/31
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.